| scholarly article | Q13442814 |
| P2093 | author name string | James H Doroshow | |
| Lee Helman | |||
| Robert Kinders | |||
| Seth M Steinberg | |||
| Joseph E Tomaszewski | |||
| Anthony J Murgo | |||
| Martin Gutierrez | |||
| Shivaani Kummar | |||
| Larry Rubinstein | |||
| Ralph E Parchment | |||
| Sherry Yang | |||
| Jennifer Low | |||
| Jerry Collins | |||
| Oxana Pickeral | |||
| Robert Wiltrout | |||
| P2860 | cites work | Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms | Q24802402 |
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Concordance of the toxicity of pharmaceuticals in humans and in animals | Q33921168 | ||
| Clinical trial design for target-based therapy | Q34981120 | ||
| Improving the evaluation of new cancer treatments: challenges and opportunities | Q35097381 | ||
| Rethinking clinical trials for cytostatic drugs | Q35166825 | ||
| Drug development in oncology: classical cytotoxics and molecularly targeted agents | Q35827606 | ||
| Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice | Q35829431 | ||
| Receptor imaging in oncology by means of nuclear medicine: current status | Q35874804 | ||
| Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy | Q36273188 | ||
| Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies | Q36466906 | ||
| Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | Q36622291 | ||
| Pharmacologically guided phase I clinical trials based upon preclinical drug development | Q41197801 | ||
| Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q44567807 | ||
| Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studies | Q46587142 | ||
| Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? | Q46607034 | ||
| Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study | Q53618262 | ||
| Matrix metalloproteinase inhibitors: how can we optimize their development? | Q73826631 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | timeline | Q186117 |
| P304 | page(s) | 131-139 | |
| P577 | publication date | 2007-02-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Compressing drug development timelines in oncology using phase '0' trials | |
| P478 | volume | 7 |
| Q41981106 | "Dead Cells Talking": The Silent Form of Cell Death Is Not so Quiet. |
| Q91721923 | A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort |
| Q35109520 | A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging |
| Q46013098 | A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. |
| Q36779225 | An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors |
| Q28472048 | Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma |
| Q37552670 | Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee |
| Q37755081 | Biomarkers and the design of clinical trials in cancer |
| Q37461714 | Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker |
| Q37139413 | Clinical biomarkers of angiogenesis inhibition |
| Q35583672 | Combining targeted therapies: practical issues to consider at the bench and bedside |
| Q33658526 | Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. |
| Q36732115 | Designing phase 0 cancer clinical trials |
| Q51527478 | Development and validation of a microfluidic chip-based nano-liquid chromatography-triple quadrupole tandem mass spectrometry method for a sensitive and reliable quantification of 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma. |
| Q34316288 | Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity |
| Q47169621 | Drug Resistance Driven by Cancer Stem Cells and Their Niche |
| Q39037597 | Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model |
| Q37790320 | Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives |
| Q42407837 | Ethical responsibility of phase 0 trials |
| Q35739362 | Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma |
| Q47816379 | Evolution of early phase clinical trials in oncology |
| Q38583655 | Experimental Therapeutic Trial Design for Pediatric Brain Tumors |
| Q39010445 | FGFR-TACC gene fusions in human glioma |
| Q39171471 | Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics |
| Q33976216 | Future prospects for biomarkers of alcohol consumption and alcohol-induced disorders |
| Q29614974 | GammaH2AX and cancer |
| Q35616195 | Gene Expression Analysis of In Vitro Cocultures to Study Interactions between Breast Epithelium and Stroma |
| Q34134483 | Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers |
| Q86039429 | How can attrition rates be reduced in cancer drug discovery? |
| Q35949304 | Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer |
| Q33316159 | Incorporating molecular tools into early-stage clinical trials |
| Q36974700 | Inflammation and lung carcinogenesis: applying findings in prevention and treatment. |
| Q36570444 | Is it possible to protect pediatric research subjects without blocking appropriate research? |
| Q36920757 | Keap1 eye on the target: chemoprevention of liver cancer |
| Q37450898 | Maximum tolerated dose: clinical endpoint for a bygone era? |
| Q37810157 | Method Validation and Application of Protein Biomarkers: Basic Similarities and Differences from Biotherapeutics |
| Q26830493 | Metronomic therapy for gynecologic cancers |
| Q37810233 | Microdosing in early lead discovery |
| Q37750876 | Microfluidic cell arrays in tumor analysis: new prospects for integrated cytomics |
| Q28477427 | Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells |
| Q30426953 | Molecular biology and therapeutics in musculoskeletal oncology |
| Q42828526 | More Randomization in Phase II Trials: Necessary but not Sufficient |
| Q51409558 | Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report |
| Q37152009 | Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. |
| Q37458170 | Next generation oncology drug development: opportunities and challenges |
| Q57074457 | Nonprofit organizations and pharmaceutical research and development |
| Q36732058 | Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient |
| Q37836076 | Optimizing preclinical study design in oncology research |
| Q37796076 | Pathogenetic mechanisms in radiation fibrosis |
| Q38818203 | Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development |
| Q34701702 | Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 |
| Q35602195 | Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva. |
| Q37358487 | Phase 0 clinical studies in oncology |
| Q37337123 | Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q37184280 | Phase 0 clinical trials: conceptions and misconceptions |
| Q33985780 | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies |
| Q84400479 | Phase 0 exploratory clinical trials: literature review 2006-2009 |
| Q34802510 | Phase 0 trials: expediting the development of chemoprevention agents |
| Q37398551 | Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts |
| Q83911864 | Primary brain tumours in adults |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q34207034 | Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy |
| Q28537857 | Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma |
| Q30432257 | Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse |
| Q38088713 | Re-overcoming barriers in translating biomarkers to clinical practice |
| Q37367075 | Retinoid chemoprevention trials: cyclin D1 in the crosshairs |
| Q36426742 | Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors |
| Q43775404 | Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus |
| Q36528175 | Targeted molecular imaging in oncology: focus on radiation therapy |
| Q34095802 | The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management |
| Q39769308 | The Role of Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling in Drug Discovery and Development |
| Q26861274 | The Valley of Death in anticancer drug development: a reassessment |
| Q47161072 | The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). |
| Q37488194 | The ethics of clinical trials |
| Q36611045 | The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials |
| Q33656349 | The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases |
| Q37187098 | The role of clinical imaging in oncological drug development |
| Q37515513 | The statistics of phase 0 trials |
| Q37055147 | Therapeutic Applications of Herbal Medicines for Cancer Patients |
| Q37137006 | Translational research in glioblastoma multiforme: molecular criteria for patient selection. |
| Q38257126 | Translational research in oncology--10 years of progress and future prospects |
| Q36275971 | Treatment of HER2-positive metastatic breast cancer following initial progression |
| Q28073826 | Unveiling changes in the landscape of patient populations in cancer early drug development |
| Q46597773 | Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements |
| Q36737058 | Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues |
| Q38316075 | Veterinary oncology clinical trials: design and implementation. |
| Q36532173 | Wharton's Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer Cells In Vitro |
Search more.